Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

SNDX - Syndax Pharmaceuticals, Inc. So'nggi... | Finranks

Home

SNDX

S

Syndax Pharmaceuticals, Inc. (SNDX)

NMS – Real vaqt narxi. Valyuta: USD

23.49

-1.21 (-4.90%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

23.95

+0.46 (1.96%)

Bozordan keyin: Mar 27, 2026, 7:52 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset

DAFNA Capital Management sold 222,847 SNDX shares in the fourth quarter for an estimated roughly $4 million. Meanwhile, the quarter-end position value decreased by $1.87 million, reflecting both trading and price movements.

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter. Meanwhile, the quarter-end position value increased by $38.07 million, reflecting both trading and share price changes.

Syndax Pharma: Two Drug Launches Fuel Transformational Growth

Syndax Pharma: Two Drug Launches Fuel Transformational Growth

Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to access a $5 billion+ AML market, with 1L Phase 3 trials as a major catalyst. Niktimvo's strong launch in GVHD and operational leverage support increasing collaboration revenue, with potential market doubling via frontline studies.

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment

Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement.

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company granted inducement awards to purchase up to 81,600 shares of common stock to three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Videolar

No Data

There is no data to display

Press-relizlar

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company granted inducement awards to purchase up to 81,600 shares of common stock to three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2 IPF trial of axatilimab; topline data expected in 4Q26 – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the Company granted inducement awards to purchase up to 11,600 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.